A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma

Cancer Chemotherapy and Pharmacology

Volumn 79, Issue 4, 2017, Pages 697-703

  Mahalingam, Devalingam ^a,b   Fountzilas, Christos ^a   Moseley, Jennifer ^a,b   Noronha, Nicole ^c   Tran, Hue ^c   Chakrabarty, Romit ^c   Selvaggi, Giovanni ^c   Coffey, Matthew ^c   Thompson, Brad ^c   Sarantopoulos, John ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CTRC Institute for Drug Development   (United States)

^c ONCOLYTICS BIOTECH INC   (Canada)

Author keywords

Melanoma; Oncolytic virus; Pelareorep; REOLYSIN ; Reovirus

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CREATININE; DACARBAZINE; PACLITAXEL; PELAREOREP; ANTINEOPLASTIC AGENT;

ABDOMINAL DISTENSION; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELLULITIS; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEVICE INFECTION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; DYSURIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LIMB PAIN; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MACULOPAPULAR RASH; MALE; MEDICAL DEVICE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SKIN METASTASIS; SPINAL CORD COMPRESSION; STAPHYLOCOCCUS INFECTION; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ADULT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MAMMALIAN ORTHOREOVIRUS 3; MELANOMA; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAMMALIAN ORTHOREOVIRUS 3; MELANOMA; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; PACLITAXEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015071483     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-017-3260-6     Document Type: Article

References (27)

1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. doi:10.3322/caac.21332
2. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4(12):748–759
3. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C (2016) Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer 53:125–134. doi:10.1016/j.ejca.2015.09.013
4. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282(5392):1332–1334
5. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 17 (12):3351–3362
6. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA (2008) Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 15(18):1257–1270
7. ®) in patients with advanced solid tumors. Invest New Drugs 31(3):696–706. doi:10.1007/s10637-012-9865-z
8. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K (2012) Phase II trial of intravenous administration of reolysin[reg] (reovirus serotype-3-dearing strain) in patients with metastatic melanoma. Mol Ther 20(10):1998–2003
9. Prestwich RJ, Errington F, Ilett EJ, Morgan RSM, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Am Assoc Cancer Res 14(22):7358–7366. doi:10.1158/1078-0432.ccr-08-0831
10. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Am Assoc Cancer Res 15(13):4374–4381. doi:10.1158/1078-0432.ccr-09-0334
11. White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15(12):911–920. http://www.nature.com/gt/journal/v15/n12/suppinfo/gt200821s1.html
12. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K (2008) Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Am Assoc Cancer Res 14(1):259–269. doi:10.1158/1078-0432.ccr-07-1510
13. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon C-S, Waisman DM, Lee PWK (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63(2):348–353
14. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN (2006) Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106(2):375–382. doi:10.1002/cncr.21611
15. Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13(5):531–536. doi:10.1097/01.cmr.0000056274.56735.c6
16. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG (2002) Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25(3):283–286
17. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ (2012) Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Am Assoc Cancer Res 18(7):2080–2089. doi:10.1158/1078-0432.ccr-11-2181
18. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R (2009) Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Am Assoc Cancer Res 15(19):6158–6166. doi:10.1158/1078-0432.ccr-09-0796
19. Sei S, Mussio JK, Yang Q-e, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE (2009) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8:47–47. doi:10.1186/1476-4598-8-47
20. ® (reovirus type 3 dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of the lung. Am Assoc Cancer Res 12(11 Supplement):C70-C70. doi:10.1158/1535-7163.targ-13-c70
21. Villalona-Calero MA, Lam E, Otterson GA, Zhao WQ, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV (2016) Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer 122(6):875–883. doi:10.1002/cncr.29856
22. Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye YN, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2798. doi:10.1200/jco.2014.58.3377
23. Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM, Chou J, Kaufman H (2014) Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstr 32(15_suppl):9029
24. Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chou J, Kaufman H (2015) Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstr 33(15_suppl):9063
25. Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon JS, Fernandez E, Kirkwood JM, Gajewski T, Gause CK, Chen L, Gorski K, Anderson A, Kaufman DR, Chou J, Hodi FS (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. ASCO Meeting Abstr 34 (15_suppl):9568
26. Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ (2015) BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Mol Ther 23(5):931–942. doi:10.1038/mt.2015.15
27. Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz R-M, Pandha H, Harrington K, Coffey M, Melcher A, Vile R (2016) combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 24(1):166–174. doi:10.1038/mt.2015.156